CAS: 3571-53-7; [(8R,9S,13S,14S,17S)-3-Hydroxy-13-Methyl-6,7,8,9,11,12,14,15,16,17-Decahydrocyclopenta[a]Phenanthren-17-Yl] Undecanoate

上下游产品

CAS号1263-57-6 estradiol diund... | CAS号50-28-2 雌二醇

雌二醇二十一烷酸酯置于sodium Hydroxide体系中,化学反应生成 十一酸雌二醇
参考文献:Gauthier Et Al.,Annales Pharmaceutiques Francaises,1958,Vol. 16,P. 757,760,762
标题:Gauthier Et Al.,Annales Pharmaceutiques Francaises,1958,Vol. 16,P. 757,760,762

专利信息

专利号:US-2022117976-A1
优先权日:2018-10-16
标 题 :Synthesis and processing of poly(pro-drug) materials for extended drug release and uses thereof
发明人：PALERMO EDMUND FRANCIS; D'AMATO ANTHONY RICHARD; GILBERT RYAN J; ELLMAN SAMUEL
权利人:RENSSELAER POLYTECH INST
摘要:The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself. In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile, Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient. These materials are enticing for a myriad of biomedical applications, including veterinary medicine, cancer treatments, birth control, and hormone replacement therapy.

专利号:US-11202834-B2
优先权日:2018-10-16
标题:Synthesis and processing of poly(pro-drug) materials for extended drug release and uses thereof
发明人：PALERMO EDMUND FRANCIS; D'AMATO ANTHONY RICHARD; GILBERT RYAN J; ELLMAN SAMUEL
权利人:RENSSELAER POLYTECH INST
摘要:The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself. In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile. Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient. These materials are enticing for a myriad of biomedical applications, including veterinary medicine, cancer treatments, birth control, and hormone replacement therapy.

专利号:WO-2020081684-A1
优先权日:2018-10-16
标题:Synthesis and processing of poly(pro-drug) materials for extended drug release and uses thereof

专利号:RU-2056421-C1
优先权日:1989-06-09
标 题 :4/4/4/4/2-(2,4-difluorophenyl)-2-(1h-azolylmethyl)-1,3-dioxol- ane-4-(methoxy)-(phenyl)-1-piperazinyl/-phenyl/-triazolones or -imidazole, method of their synthesis, antifungal composition and a method of struggle against fungi in warm-blooded animals

专利号:US-2021308268-A1
优先权日:2018-10-16
标题:Synthesis and processing of poly(pro-drug) materials for extended drug release and uses thereof